

## DAFTAR PUSTAKA

1. World Health Organization (WHO). Breast Cancer [Internet]. 2021 [cited 2021 Dec 15]. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
2. International Agency for Research on Cancer WHO. Cancer Tomorrow [Internet]. 2022 [cited 2022 Jan 12]. Available from: [https://gco.iarc.fr/tomorrow/en/dataviz/tables?cancers=20&single\\_unit=10000&populations=903\\_904\\_905\\_908\\_909\\_935&years=2025](https://gco.iarc.fr/tomorrow/en/dataviz/tables?cancers=20&single_unit=10000&populations=903_904_905_908_909_935&years=2025)
3. World Health Organization. Indonesia Fact Sheets [Internet]. 2020 [cited 2021 Dec 8]. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>
4. Sukmayenti, Nirmala Sari. Hubungan faktor reproduksi dengan kejadian kanker payudara pada wanita di RSUP dr. m. djamil padang. *Jurnal Riset Hesti Medan*. 2018;3(2).
5. Saha T, Solomon J, Samson AO, Gil-Henn H. Invasion and metastasis as a central hallmark of breast cancer. *J Clin Med*. 2021 Aug 2;10(16).
6. Yeeravalli R, Das A. Molecular mediators of breast cancer metastasis. *Hematology/ Oncology and Stem Cell Therapy*. 2021 Dec 1;14(4):275–89.
7. Tan AR. *Triple-Negative Breast Cancer: A Clinician's Guide*. Springer International Publishing AG; 2018.
8. Adiputra PAT, Sudarsa IW. Skoring prognostik survival pasien triple negative breast cancer berbasis immunoscore. *JBN (Jurnal Bedah Nasional)*. 2021 Jul 17;5(2):65.
9. Allan Wahyu Permana K, Agung Yudistira Permana M, Nisa S, Kedokteran F, Lampung U, Ba R, et al. Asosiasi triple negative breast cancer (TNBC) dengan mutasi BRCA-1 dan etnisitas. *Medula*. 2019;9:398.
10. American Joint Committee on Cancer. *AJCC Cancer Staging Manual: Eight Edition*. Chicago ; 2017.
11. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study [Internet]. Vol. 8, *Oncotarget*. 2017. Available from: [www.impactjournals.com/oncotarget/](http://www.impactjournals.com/oncotarget/)
12. Helmi AF, Khambri D, Rustam R. The relationship of breast cancer subtypes with the event of metastasis in dr. m. djamil hospital padang. *Bioscientia Medicina : Journal of Biomedicine and Translational Research*. 2021 Oct 7;5(4):1199–205.
13. Kementerian Kesehatan Republik Indonesia. *Panduan Penatalaksanaan Kanker Payudara* [Internet]. [cited 2022 Feb 6]. Available from: <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
14. Alkabban FM, Ferguson T. *Breast Cancer*. 2021 [cited 2022 Feb 6]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>
15. Watkins EJ. Overview of breast cancer. *J Am Acad Physician Assist*. 2019 Oct 1;32(10):13–7.

16. Bose SM, Sharma SC, Mazumdar A, Kaushik R. Breast Cancer Comprehensive Management. Springer Nature Singapore; 2022.
17. Kabel AM, Baali FH. Breast cancer: insights into risk factors, pathogenesis, diagnosis and management. *Journal of Cancer Research and Treatment* [Internet]. 2015;3(2):28–33. Available from: <http://pubs.sciepub.com/jcrt/3/2/3>
18. Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast Ccancer: a review for breast radiologists. *J Breast Imaging* [Internet]. 2021 Jan 1;3(1):12–24. Available from: <https://doi.org/10.1093/jbi/wbaa110>
19. Atoui A, Bou Zerdan M, El Mahmoud A, Chamseddine N, Hamad L, Assi HI. Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon. *Int J Breast Cancer*. 2022;2022.
20. Fan Y, He S. The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. Vol. 14, *Cancer Management and Research*. Dove Medical Press Ltd; 2022.
21. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Vol. 22, *Breast Cancer Research*. BioMed Central Ltd; 2020.
22. Veronesi U, Goldhirsch A, Veronesi P, Gentilini OD, Leonardi MC. *Breast Cancer: Innovation in Research and Management*. Springer International Publishing; 2017.
23. Tungsukruthai S, Petpiroon N, Chanvorachote P. Molecular mechanisms of breast cancer metastasis and potential anti-metastatic compounds. *Anticancer Res*. 2018 May 1;38(5):2607–18.
24. Aydiner A, Igci A, Soran A. *Breast Cancer: A Guide to Clinical Practice*. Switzerland: Springer Nature ; 2019.
25. Doloksaribu RF, Alferraly TI, Betty. Claudin-7 expression in triple negative breast cancer based on histopathological type and grade. *Int J Chemtech Res*. 2019;12(02):197–202.
26. Anna Bethania K, Rustamadji P. Hubungan sub tipe molekular pada karsinoma payudara invasif dengan grade, invasi limfovaskular dan metastasis KGB di departemen patologi anatomik FKUI/RSCM tahun 2019. *Maj Patol Indones*. 2022;31(3):392–9.
27. Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: A population-based study. *Cancer Manag Res*. 2018;10:5329–38.
28. Jin X, Mu P. Targeting breast cancer metastasis. *Breast Cancer (Auckl)*. 2015 Sep 2;9:23–34.
29. Lv Y, Ma X, Du Y, Feng J. Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets. Vol. 14, *OncoTargets and Therapy*. Dove Medical Press Ltd; 2021. p. 589–607.
30. Surahman, Rachmat M, Supardi S. *Metodologi Penelitian*. Kementerian Kesehatan Republik Indonesia; 2016.
31. Haruna M, Daramola AO, Awolola NA, Badr NM, Fehintola Banjo AA, Shaaban A. Clinicopathological features and androgen receptor expression

- in triple negative breast cancer at Lagos, Nigeria. *Ecancermedicalsecience*. 2022 Oct 3;16.
32. Makar WS. Clinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt. *Research in Oncology*. 2019 Jun 1;15(1):31–4.
  33. Gulbahce HE, Bernard PS, Weltzien EK, Factor RE, Kushi LH, Caan BJ, et al. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis. *Cancer*. 2018 Dec 15;124(24):4676–84.
  34. Sidrah Nadira C, Rizka A, Humaira Z. Faktor keterlambatan pada pasien kanker payudara yang berobat di rsucm aceh utara tahun 2020 -2021. *Jurnal Ilmiah Manusia dan Kesehatan*. 2023;
  35. Subiyanto D, Kadi TA, Ismayiah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan Grading Histopatologi. *Media Penelitian dan Pengembangan Kesehatan*. 2021 Dec 13;31(3):193–202.
  36. Hadiyanto AVS, Miranti IP, Prajoko YW, Istiadi H. Histological and Clinical Stage Profiles of Young-aged Breast Carcinoma. *Diponegoro International Medical Journal*. 2022 Jul 29;3(1):1–6.
  37. Silva JL da, Paula BHR de, Small IA, Thuler LCS, Melo AC de. Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort. *Breast Cancer (Auckl)*. 2020;14.
  38. De La Cruz Ku G, Luyo M, Morante Z, Enriquez D, Möller MG, Chambergo-Michilot D, et al. Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. *PLoS One*. 2020 Aug 1;15(8 August 2020).
  39. Anwar SL, Avanti WS, Nugroho AC, Choridah L, Dwianingsih EK, Harahap WA, et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: A hospital-based study in Indonesia. *World J Surg Oncol*. 2020 May 30;18(1).
  40. Casas SD, Lancheros García EL, Sánchez Campo A, Sanchez Pedraza R, Roman Vasquez V, Mendoza SD, et al. Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women. *Cureus*. 2019 Jun 21;
  41. Gnanamuttupulle M, Henke O, Ntundu SH, Serventi F, Mwakipunda LE, Amsi P, et al. Clinicopathological characteristics of breast cancer patients from Northern Tanzania: Common aspects of late stage presentation and triple negative breast cancer. *Ecancermedicalsecience*. 2021;15.
  42. Kennedy WR, Tricarico C, Gabani P, Weiner AA, Altman MB, Ochoa LL, et al. Predictors of distant metastases in triple-negative breast cancer without pathologic complete response after neoadjuvant chemotherapy. *JNCCN Journal of the National Comprehensive Cancer Network*. 2020;18(3):288–96.
  43. Haholongan DD, Ali I, Tanggo EH. Relationship of Obesity Recurrence Events in Triple Negative Breast Cancer Patients in Dr. Soetomo General Hospital Surabaya. *Scientific Journal of Health Science* . 2020;



44. Bhattacharjee A, Hossain AA, Yeasmin S, Akter T. Incidence, Epidemiology and Clinico-Pathological Status of Different Molecular Subtypes of Breast Cancer in NICRH, Dhaka. *Delta Med Col J* . 2018;
45. Gunardi H, Kartini D. Association between Obesity and Hormone Receptor Characteristics of Primary Breast Cancer at Cipto Mangunkusumo General Hospital, Jakarta, in 2017. *The New Ropanasuri Journal of Surgery* [Internet]. 2019 Dec 31; Available from: <https://scholarhub.ui.ac.id/nrjs/vol4/iss2/3/>
46. Li SY, Li YW, Ma D, Shao ZM. Prediction of axillary lymph node metastasis in triple-negative breast cancer by multi-omics analysis and an integrated model. *Ann Transl Med*. 2022 Jun;10(11):623–623.
47. Widodo I, Dwianingsih EK, Aryandono T, Soeripto. Clinicopathological characteristic and prognostic significance of Indonesian triple negative breast cancer. *Indonesian Biomedical Journal*. 2019;11(3):286–92.
48. Goyal S, Jacob LA, Lokanatha D, Suresh Babu MC, Lokesh KN, Rudresha AH, et al. Discordance in clinical versus pathological staging in breast cancer: Are we undermining the significance of accurate preoperative staging in the present era? *Breast Dis*. 2021 Nov 5;41(1):115–21.
49. Navarro DTSM, Aguiar MG de, Galvão MF de O, Germano TCO, Lajus TBP, Oliveira TCA de. Clinical and histopathological axillary assessment. *Mastology*. 2018 Mar;28(1):7–10.
50. Singh D, Mukherjee S. Impact of Molecular Subtypes of Breast Cancer on Axillary Lymph Node Metastasis: A Tertiary Center Experience. *Archives of Breast Cancer*. 2021 Oct 31;305–12.
51. Chen H, Ding A, Wang M, Yin C, Zhang Z. Prognostic significance of lymph node metastasis in triple negative ductal carcinoma of the breast: a retrospective cohort study [Internet]. Vol. 10, *Int J Clin Exp Med*. 2017. Available from: [www.ijcem.com/](http://www.ijcem.com/)
52. Yao Y, Chu Y, Xu B, Hu Q, Song Q. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. *Biosci Rep*. 2019 Jun 4;39(6).
53. Leny Kurnianingrum L, Tjahjadi H. Profil Klinikopatologik Karsinoma Payudara Invasif Metastasis Jauh di Departemen Patologi Anatomi FKUI/RSCM Tahun 2019. *Maj Patol Indones*. 2022;31(3):359–67.
54. Gu Y, Wu G, Zou X, Huang P, Yi L. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis. *Medical Science Monitor*. 2020 Jan 21;26.
55. Johnson J, Chow Z, Lee E, Weiss HL, Evers BM, Rychahou P. Role of AMPK and Akt in triple negative breast cancer lung colonization. *Neoplasia (United States)*. 2021 Apr 1;23(4):429–38.
56. Chen S, Yang J, Liu Y, You H, Dong Y, Lyu J. Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases. *PeerJ*. 2019 Dec 17;7:e8298.
57. Benli Yavuz B, Aktan M, Kanyilmaz G. Prognostic Factors in Patients with Triple Negative Breast Cancer Undergoing Adjuvant Radiotherapy: A 10-Year Single Center Experience. *Archives of Breast Cancer*. 2022 May 15;377–85.

58. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Annals of Oncology*. 2021 Dec;32(12):1475–95.
59. Akinyi MO, Dan K, Daniel OK, Edwin W. Correlation between receptor status and presence of axillary lymph node metastasis in breast cancer in Kenya. *Annals of African Surgery*. 2019;16(2):51–4.
60. Cai S long, Wei R mei, Han L, Chen X geng, Gong G xian, Lin X quan, et al. Risk factors of non-sentinel lymph node metastasis in 443 breast cancer patients with sentinel lymph node-positive. *Medicine*. 2022 Jul 22;101(29):e29286.
61. Zawawy S, Khedr G. Pattern of Failure and Treatment Results in Triple Negative Breast Cancer Patients. *Adv Breast Cancer Res*. 2022;11(02):75–88.
62. Altinok A. Prognostic Role of Family History in Patients with Triple Negative Breast Cancer. *Turkish Journal of Oncology*. 2020;
63. Min SK, Lee SK, Woo J, Jung SM, Ryu JM, Yu J, et al. Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. *J Breast Cancer*. 2021;24(1):75.
64. Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Häkkinen J, Larsson C, et al. Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. *Clinical Cancer Research*. 2019 Nov 1;25(21):6368–81.
65. Kunikullaya S, Poddar J, Sharma A, Patel S. Pattern of distant metastasis in molecular subtypes of carcinoma breast: An institutional study. *Indian J Cancer*. 2017;54(1):327.
66. Harahap SN, Khambri D, Triputra Y, Tofrizal, Yetti H. The Relationship of Programmed Death-Ligand 1 Expression to the Survival of Triple Negative Breast Cancer Patients in West Sumatera. *Neuro Quantology*. 2022;

